John Fezza, MD
Ophthalmic Plastic and Reconstructive Surgery · Venice, FLNPI 1184715187
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (59.7%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. AbbVie accounts for 98.8% of it on its own, with 12 other manufacturers making up the rest. Among ophthalmic plastic and reconstructive surgery clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 3,127 payments — averaging $1152.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3.6M
- Visant Medical, Inc.$30K
- Merz North America, Inc.$5K
- Nordic Pharma, Inc.$5K
- Galderma Laboratories, L.p.$4K
- Revance Therapeutics, Inc.$149
- plus $441 from 7 others
Across 25 payments — averaging $14,279 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merz North America, Inc.$314K
- AbbVie$43K
What the payments were for
- Royalty or licence$30,0001%
- Consulting fees$1,003,88428%
- Speaking & faculty fees$2,150,92360%
- Travel & lodging$358,13810%
- Food & beverage$62,0492%
- Education$810%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 3,064 | $3,560,302 |
| Visant Medical, Inc. | 3 | $30,000 |
| Merz North America, Inc. | 30 | $5,406 |
| Nordic Pharma, Inc. | 1 | $4,999 |
| Galderma Laboratories, L.p. | 20 | $3,777 |
| Revance Therapeutics, Inc. | 1 | $149 |
| Sun Pharmaceutical Industries Inc. | 1 | $125 |
| Amgen | 1 | $119 |
| Oyster Point Pharma, Inc. | 1 | $82 |
| Endo Pharmaceuticals Inc. | 1 | $42 |
| Omeros Corporation | 2 | $38 |
| Boston Scientific | 1 | $19 |
| Eyevance Pharmaceuticals LLC | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,605,074 in reported general payments places this provider in the 95th percentile of 37 ophthalmic plastic and reconstructive surgery providers in Florida.
See all ophthalmic plastic and reconstructive surgery providers in Florida →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ErythromycinErythromycin Base | 866 | $7,057 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 95 | $3,439 |
| Tramadol Hcl | 383 | $728 |
| ValacyclovirValacyclovir Hcl | 38 | $552 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 65 | $526 |
| Cephalexin | 38 | $232 |
| Ondansetron OdtOndansetron | 31 | $104 |
| Zolpidem Tartrate | 28 | $69 |
| Tobramycin | 12 | $43 |
Paid to pharmacies, not to this prescriber.
Other ophthalmic plastic and reconstructive surgery in Venice
- Michael MercandettiVenice$2K
- Wendy LeeMiami$616K
- Jennifer MurdockMiami$316K
- Ana VictoriaMiami$130K
- Keshini ParbhuWindermere$102K
- Sara WesterMiami$78K
- Robert ApplebaumLakeland$39K
- Yasaman MohadjerSt Petersburg$6K
- William MackTampa$5K
- Gil EpsteinPlantation$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.